The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
1 to 10 of 2188    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Diagnostic confirmation--Heme and Lymphoid Neoplasms--Lymphoma: Is Diagnostic Confirmation "5" for Hematopoietic Neoplasms appropriate for this case? There appears to be no conclusive histologic diagnosis (Neoplasm, suggestive of lymphoma) and only the IHC/flow cytometry issued a conclusive diagnosis. See Discussion.

Final Apr 07 2020

Reportability: Is ASIN-H (high-grade anal squamous intraepithelial neoplasia) equivalent to anal intraepithelial neoplasia, III (AIN III)?

Final Mar 24 2020

Histology--Head & Neck:  Why is 8070 not listed as a valid histology for ill-defined sites as squamous cell carcinoma arises in the head and neck sites. See Discussion.

Final Mar 12 2020

Reportability/Histology--Vulva: Is Extramammary Paget neoplasm (intraepithelial glandular neoplasm) reportable? See Discussion.

Final Mar 11 2020

Tumor Size--Clinical--Breast: Does information from any type of biopsy take precedence over an imaging report? See Discussion.

Final Mar 03 2020

Solid Tumor Rules (2018)/Histology--Brain and CNS:  How are histology and primary site coded when a resection of a spine, designated intramedullary lesion, shows primary intramedullary melanocytoma? See Discussion.

Final Feb 12 2020

Solid Tumor Rules (2018)/Multiple primaries--Colon: Solid Tumor Rules 2018, Colon Rule M7, bullet 3 indicates that (if neither bullet 1 or 2 apply) a new tumor at the anastomotic site must be stated to arise in the mucosa (confirmed in SINQ 20190096) to qualify as a new primary. However, there is often no clear statement of tumor arising from or involving mucosa (unless the new tumor is limited to the mucosa) noted by pathologists in our region. Do any of the following examples imply a new tumor arising in mucosa per Rule M7, bullet 3?  See Discussion.

Final Feb 05 2020

Multiple primaries--Heme & Lymphoid Neoplasms: How many primaries are accessioned for a patient diagnosed with myelodysplastic syndrome (MDS) with ring sideroblasts in 2005, and stated to have progressed to high risk disease/early evolving acute myeloid leukemia (AML) in 09/2019? See Discussion.

Final Jan 30 2020

Race: How should race information from linkages be incorporated into the coding of Race? See Discussion.


Final Jan 22 2020

Solid Tumor Rules (2018)/Histology--Head & Neck: How is histology coded for a glossotonsillar sulcus tumor with both squamous cell carcinoma and mucoepidermoid carcinoma? See Discussion.

Final Jan 22 2020
Next 10 >